Skip to main content
NewslettersWatchlist

Essa Pharma(EPIX-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low0.1899
Day High0.2070
Open:0.2000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Essa Pharma

Select a category then submit the form to load news
Newswire.ca
Investors in Essa Pharma Inc. (NASDAQ: EPIX) are urged to contact Siskinds LLP about its investigation into a potential class action
Tipranks
ESSA Pharma Completes Acquisition by XenoTherapeutics
Newswire.ca
ESSA Announces Completion of Arrangement with XenoTherapeutics
Tipranks
ESSA Pharma Securityholders Approve Acquisition by XenoTherapeutics
Newswire.ca
ESSA Securityholders Approve Acquisition by XenoTherapeutics
Tipranks
ESSA Pharma Faces Class Action Lawsuit in California
Tipranks
ESSA Pharma Receives Court Approval for Acquisition
Newswire.ca
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order
Tipranks
ESSA Pharma Amends Agreement with XenoTherapeutics, Adjusts Shareholder Terms
Newswire.ca
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Tipranks
ESSA Pharma Reschedules Special Meeting for Acquisition
Newswire.ca
Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025
Tipranks
ESSA Pharma Clarifies Share Trading Period Details
Newswire.ca
Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution
Tipranks
ESSA Pharma Reports Q2 Loss Amid Strategic Transition
Tipranks
ESSA Pharma Announces $80M Capital Distribution
Newswire.ca
Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution
Tipranks
ESSA Pharma Announces $80 Million Shareholder Distribution Amid Acquisition
Newswire.ca
Essa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders
Tipranks
ESSA Pharma Announces Tax Implications of Cash Distribution
Tipranks
ESSA Pharma Seeks Court Approval for Cash Distribution Amid XenoTherapeutics Merger
Tipranks
ESSA Pharma to be Acquired by XenoTherapeutics in All-Cash Deal
Newswire.ca
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders
Tipranks
ESSA Pharma to be Acquired by XenoTherapeutics
Business Wire
EPIX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of ESSA Pharma Inc. is Fair to Shareholders
Newswire.ca
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
Newswire.ca
ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025
Tipranks
EPIX Lawsuit Alert! Class Action Lawsuit Against ESSA Pharma, Inc.
Newswire.ca
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
Newswire.ca
ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024
Newswire.ca
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
Newswire.ca
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Profile

ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.